Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I

20 Aug 2015

Abstract excerpt

// Guang Yang 1 , Minjie Gao 1 , Yiwen Zhang 1 , Yuanyuan Kong 1 , Lu Gao 1 , Yi Tao 1 , Ying Han 1 , Huiqun Wu 1 , Xiuqin Meng 1 , Hongwei Xu 2 , Fenghuang Zhan 2 , Xiaosong Wu 1 , Jumei Shi 1 1 Department of Hematology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China 2 Department of Internal Medicine, University of Iowa, Carver College of Medicine, Iowa City, Iowa, USA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Cell Function and Interaction
Share to Multiple Myeloma Research and Treatments
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26323098
DOI: 10.18632/oncotarget.4831

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class IPMID 26323098Read ↗

Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell–mediated lysis of myelomaSemantic proximity Read ↗

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myelomaSemantic proximity Read ↗

Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myelomaSemantic proximity Read ↗

Targeting NF-κB Signaling for Multiple MyelomaSemantic proximity Read ↗

PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γSemantic proximity Read ↗

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myelomaSemantic proximity Read ↗

Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple MyelomaSemantic proximity Read ↗

IMiD Resistance in Multiple Myeloma: Current Understanding of the Underpinning Biology and Clinical ImpactSemantic proximity Read ↗

Killer cell immunoglobulin-like receptors in Thai patients with multiple myeloma.Semantic proximity Read ↗

Synergistic Mechanisms of Traditional Chinese Medicine and Proteasome Inhibitors in Multiple Myeloma Therapy: A Comprehensive ReviewSemantic proximity Read ↗

One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.Semantic proximity Read ↗

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and AiolosSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.